Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine
Hadi Hassannia(Mazandaran University of Medical Sciences), Farhad Jadidi‐Niaragh(Tabriz University of Medical Sciences), Fatemeh Atyabi(Tehran University of Medical Sciences), Afshin Namdar(University of Alberta), Hamed Mohammadi(Tehran University of Medical Sciences), Mahshid Nosouhian(Islamic Azad University, Isfahan), Gholamabas Sabz(Yasuj University of Medical Sciences), Mehdi Yousefi(Tabriz University of Medical Sciences), Gholamreza Azizi(Jefferson Hospital for Neuroscience), Mitra Ghasemi Chaleshtari(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Ghasem Ghalamfarsa(Yasuj University of Medical Sciences), Sajad Hasanzadeh(Yasuj University of Medical Sciences), Ali Masjedi(Tabriz University of Medical Sciences)
Cited by 102
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
|International Immunopharmacology|2022|384
Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment
|Frontiers in Immunology|2022|363
Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management
|Scandinavian Journal of Immunology|2020|339
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312